Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
Biomedical breakthroughs could become a “casualty” of President Donald Trump’s plan to boost defense spending by $54 billion, Sen. Edward J. Markey (D-Mass.) said at a personalized medicine briefing.
“You have to ask yourself, ‘What is the real fear that people have?’ Is it a terrorist in Fallujah or Mosul?” Markey asked, naming cities in Iraq. “Or is it the terror of a phone call that another member of your family has that disease?”
The Massachusetts senator, who said his state receives more research dollars per capita from the National Institutes of Health than any other state, made the case for maintaining research funding and other social programs one day after Republicans released their plan to replace the Affordable Care Act. While health-care reform has divided Republicans and Democrats, members of both parties support funding for medical research.
“In 2017, we’re at a critical juncture as we debate the future of health care in this country,” Markey said of how to ensure people are getting care they need and can afford.
Edward Abrahams, president of the Personalized Medicine Coalition, said by tailoring treatments to the individual, precision medicine will make health-care delivery more efficient and therefore less expensive.The coalition hosted the briefing to draw attention to precision medicine, an emerging approach for disease treatment and prevention that seeks to maximize effectiveness by taking into account individual differences and lifestyle, environment and genes. The bipartisan 21st Century Cures law ( Pub. L. 114-255) to promote medical innovation provided funding for precision medicine, but that funding must be reauthorized every year.
A report from the coalition found a growing market for personalized medicines, citing a 62 percent increase since 2012 in the number of them on the market.
Stephen L. Eck, vice president of oncology medical sciences, Astellas Pharma Global Development, also said the drug industry as a whole has moved toward developing drugs for specialized populations.
“We can become more efficient in developing drugs,” he said, adding personalized medicine is a good business model because “we can deliver a product that’s of much higher value in a much shorter period of time.”
At the same time, the coalition’s report found that uncertainty in the future of regulation, such as whether the Food and Drug Administration will regulate laboratory-developed tests, is discouraging investment in innovative molecular diagnostics.
The FDA issued draft guidance in 2014 proposing to regulate these tests but ultimately decided not to finalize the document amid disagreements between clinical laboratories and the device industry. Diagnostics are critical to precision medicine because doctors use the tools to determine whether a patient will benefit from a specific treatment.
The briefing occurred in a Senate office building one day before the Senate Appropriations Committee planned to hold a hearing on medical research.
While there are no funding details available for fiscal year 2018, the president has said he wants to boost federal defense spending by $54 million by cutting discretionary spending, which includes the NIH budget.
“Some things become casualties because you’ve drained so many of your revenues,” Markey said.
If the NIH experienced a funding cut, it would occur just after the Cures law expressly provided money for the agency. It would also come right after the NIH saw a $2 billion increase in 2016, the largest increase in a dozen years. That boost started to reverse a 22 percent decrease in purchasing power and brought the NIH’s annual budget up to $32 billion. Senate appropriators approved another $2 billion increase for the agency last summer, but Congress stopped work on its spending plan for FY 2017 to allow Trump to weigh in on spending.
“If they have massive tax cuts plus a massive defense spending increase plus a massive wall [on the U.S.-Mexico border]—and they continue to say they want to balance the budget— well, something has to go,” Markey told Bloomberg BNA after his remarks. “You don’t have to be a genius detective to figure out what’s left.”
The nation should be aspiring to lead medical breakthroughs, he said, through robust NIH funding.
“Medical research is the field of dreams, from which we harvest the findings that give hopes to families,” Markey said.
To contact the reporter on this story: Jeannie Baumann in Washington at email@example.com
To contact the editor responsible for this story: Randy Kubetin at RKubetin@bna.com
More information about the Personalized Medicine Coalition briefing is available at http://bit.ly/2mudlDJ. The report is available at http://www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/The-Personalized-Medicine-Report1.pdf.
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)